Dr. Radhika V. Walling

Oncology | Hematology | Hematology Oncology
7229 Clearvista Dr, Symptom Management Group, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
7229 Clearvista Dr, Symptom Management Group, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Radhika Walling is an Oncologist and a Hematologist in Indianapolis, Indiana. Dr. Walling is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Gastroesophageal Junction Cancer, Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Walling is currently accepting new patients.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin
Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Community Hospital North
Community Hospital East
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

COMMUNITY PHYSICIANS OF INDIANA INC
7229 Clearvista Dr, Symptom Management Group, Indianapolis, IN 46256

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

4 Total Publications

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2021
Similar Doctors
Advanced in DICER1 Syndrome
Dr. Nawal Kassem
Hematology Oncology | Oncology
Advanced in DICER1 Syndrome
Dr. Nawal Kassem
Hematology Oncology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (9.9 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nawal Kassem is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Kassem is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Li-Fraumeni Syndrome, Paget Disease of the Breast, and HER2 Negative Breast Cancer.

Experienced in DICER1 Syndrome
Dr. Jacqueline K. Joyce
Hematology Oncology | Hematology | Oncology
Experienced in DICER1 Syndrome
Dr. Jacqueline K. Joyce
Hematology Oncology | Hematology | Oncology

Indiana University Health Southern Indiana Physicians LLC

719 W 2nd St, 
Bloomington, IN 
 (57.6 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jacqueline Joyce is a Hematologist Oncology specialist and a Hematologist in Bloomington, Indiana. Dr. Joyce is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Joyce is currently accepting new patients.

Experienced in DICER1 Syndrome
Dr. Tarah J. Ballinger
Hematology Oncology | Oncology | Hematology
Experienced in DICER1 Syndrome
Dr. Tarah J. Ballinger
Hematology Oncology | Oncology | Hematology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (9.9 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tarah Ballinger is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Ballinger is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Hormone Replacement Therapy (HRT). Dr. Ballinger is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walling's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile